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AQUEOUS METHOD FOR MAKING 
MAGNETIC IRON OXIDE NANOPARTICLES 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This is a continuation application of U.S. patent applica-
tion Ser. No. 13/855,706 filed on Apr. 2, 2013, which is a 
continuation application of U.S. patent application Ser. No. 
12/174,169 filed on Jul. 16, 2008, which claims priority from 
U.S. provisional patent application No. 60/949,945 filed on 
Jul. 16 2007, each of which is incorporated herein by refer-
ence in its entirety. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
This invention was made with govermnent support under 
National Institutes of Health grant number KOi CAlOl 781. 
The government has certain rights in the invention. 
FIELD OF THE INVENTION 
The present invention relates to the field ofbiosensors and, 
more particularly to a method of making magnetic iron oxide 
nanoparticles coated with a polymer and functionalized with 
a ligand and the nanoparticles made accordingly. 
BACKGROUND OF THE INVENTION 
Iron oxide based magnetic nanocrystals have been widely 
used in a variety of biomedical applications such as diagnos-
tic, magnetic resonance imaging (MRI) and in magnetically 
guided site specific drug delivery systems. Their use as MRI 
contrast agents and as an enhancer in hypothermia (heating of 
diseased tissue by application of an RF pulse) has been widely 
discussed in the literature. Recently, it has been found that 
dextran coated iron oxide nanoparticles, ranging in size from 
1 to 100 nm, can be used as magnetic relaxation switches 
(MRS) or magnetic relaxation nanosensors (MRnS). When 
these nano sensors self assemble in the presence of a molecu-
lar target, there is a significant change in the spin spin relax-
ation time (T2) of neighboring water molecules. This param-
eter (T2) is a component of the MR signal. The observed 
target-induced self assembly of iron oxide based nanopar-
ticles has been used as a sensitive detection method for vari-
ous targets and reported in the literature. 
SUMMARY OF THE INVENTION 
With the foregoing in mind, the present invention advan-
tageously provides iron oxide nanoparticles that have been 
specifically prepared for in vivo studies and for clinical appli-
cations, as injectable MRI contrast agents. 
Monodisperse, water-soluble dextran-coated iron oxide 
nanorods were synthesized using a facile and scalable 
method. Our room temperature method involves the mixing 
of an acidic solution of iron salts with a basic solution of 
ammonium hydroxide to facilitate initial formation of iron 
oxide crystals. The stability, cystallinity and shape of these 
nanorods depend on the time ofaddition of the dextran as well 
its degree of purity. The as-synthesized nanorods exhibit 
unique magnetic properties, including superparamagnetic 
behavior and high spin-spin water relaxivity (R2). Addition-
ally, they posses enhanced peroxidase activity when com-
pared to those reported in the literature for spherical iron 
oxide nanoparticles. Thus, this high yield synthetic method 
2 
for polymer-coated iron oxide nanorod will expedite their use 
in applications from magnetic sensors, devices and nanocom-
posites with magnetic and catalytic properties. 
Iron oxide based magnetic nanoparticles have been widely 
used in a variety of biomedical applications such as magnetic 
separation, magnetic resonance imaging, hyperthermia, mag-
netically-guided drug delivery, tissue repair, and molecular 
diagnostics. For most applications, a polymeric coating is 
needed to improve the nanoparticles' aqueous stability, bio-
10 compatibility and conjugation properties. Typically, dextran-
coated iron oxide nanoparticles have been successfully used 
as magnetic resonance imaging (MRI) contrast agent, due to 
their strong ability to dephase water protons in surrounding 
tissue, which results in a decrease in the MRI signal. In 
15 addition, the dextran coating can be crosslinked and function-
alized with amino groups to facilitate the conjugation of 
targeting ligands for MRI and in vitro diagnostics applica-
tions. Current synthetic procedures for dextran-coated iron 
oxide nanoparticles involve the formation of the iron oxide 
20 core in the presence of dextran, as stabilizer and capping 
agent, in an alkaline solution. Under these in situ conditions, 
the nature, quality and amount of the polymer modulate the 
nucleation, growth and size of the newly formed iron oxide 
nanocrystal. A common characteristic of most reported in situ 
25 dextran-coated iron oxide nanoparticles synthetic procedures 
is the formation of nanoparticles with a spherical iron oxide 
core. Research efforts have been geared towards the produc-
tion of small, uniform and highly dispersed spherical nanoc-
rystals. Only recently, has the importance of the nanopar-
30 ticles' shape been recognized, in particular one dimensional 
(1-D) structures such as nanorods and nanotubes, because 
they exhibit unique properties that are different from their 
corresponding zero dimensional counterparts (0-D or spheri-
cal nanocrystals ). Particularly in the case of iron oxide, 1-D 
35 nanorods have been found to exhibit interesting magnetic 
properties due to their shape anisotropy, such as higher block-
ing temperatures and larger magnetization coercivity, com-
pared to their 0-D counterparts. However, their wide applica-
tion in biomedical research has been hampered by difficult 
40 and non-reproducible synthetic procedures, use of toxic 
reagents and poor yields. For instance, current methods for 
making iron oxide nanorods involve hydrothermal, sol-gel 
and high temperature procedures, among others. Therefore, a 
water-based synthetic procedure for iron oxide nanorods that 
45 is simple, economical, low temperature and high yield would 
be in high demand. In particular, synthetic methods that yield 
water soluble and stable polymer-coated nanorods would be 
ideal for studies geared towards the development of magnetic 
biosensors and magnetic devices. 
50 For these reasons, we surmised it would also be advanta-
geous to develop a new, facile, reproducible and low cost 
method to synthesize iron oxide nanoparticles for in vitro 
applications. In particular, a simple synthetic method that 
yields larger nanoparticles (100-500 nm) with a unique crys-
55 ta! shape and enhanced magnetic relaxation (high R2 and Rl) 
would be helpful in studying the effect of shape and size on 
the sensitivity of the MRS assay. 
To our understanding, it has not yet been reported what 
effect larger nanoparticles (100 to 500 nm) would have on the 
60 sensitivity of the magnetic relaxation assay. It has always 
been hypothesized that the target induced self assembly of 
large nanoparticles would result in nanoparticles clusters too 
big that they would settle down (precipitate) and therefore 
would render the system useless. However, if these nanopar-
65 ticles contain a large iron oxide crystal with a high magnetic 
relaxation (high R2), a lower amount of nanoparticles would 
be required to achieve a detectable T2 signal (MRI signal). In 
US 9,125,941 B2 
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such case, the amount of nanoparticles that participate in 
cluster formation would be small, resulting in smaller clusters 
of magnetic nanoparticles that remain suspended in solution 
and do not precipitate out. We hypothesized that having a 
lower numberof nanoparticles participating in target-induced 5 
cluster formation would result in a more sensitive assay, 
having a lower detection limit. 
4 
FIG. 6(a) is a time dependent study after addition of! µg of 
Antibody against Protein Gin 0.42 µg IO-dextran-protein G 
particles; 6(b) depicts another time dependent study where 
after addition ofl µg of Antibody against Protein Gin 0.66 µg 
IO-silica-protein G particles; 7(a) is a time dependent study; 
after addition of 51.25 CFU MAP in 0.54 µg IO-dextran-
protein G particles; control=! µI phosphate buffer, pH 7.4; 
and 7(b) is a time dependent study; after addition of 51.25 
CFU MAP in 0.82 µg IO-silica-protein G particles; con-
trol=411 phosphate buffer, pH 7.4. IO-silica-protein G was 
conjugated with antibody specific to MAP and then MAP was 
added; 
FIG. S(a) hysteresis loops obtained at temperatures SK, 
100 K and 200 K; (b) zero field cooled and field cooled 
magnetic susceptibilities in an external magnetic field H=200 
G; ( c) real and ( d) imaginary components of ac susceptibility 
at different frequencies, the inset of ( d) shows the Arrhenius 
plot obtained from the imaginary component of susceptibility 
Accordingly, here we disclose a facile, high-yield, room-
temperature, and water-based synthetic protocol that yields 
disperse dextran-coated iron oxide nanorods (DIONrods). 10 
Our synthetic procedure differs from previously reported 
methods for dextran-coated iron oxide nanoparticles in that 
the dextran is not present during the initial nucleation process. 
Instead, the dextran is added at a later stage. This "stepwise" 15 
process, as opposed to the in situ process, allows for the 
formation of stable, disperse and highly crystalline super-
paramagnetic iron oxide nanorods with unique magnetic 
properties, such as high blocking temperature and improved 
high water relaxivity. 20 measurements; and 
BRIEF DESCRIPTION OF THE DRAWINGS 
The patent or application file contains at least one drawing 
executed in color. Copies of this patent or patent application 25 
publication with color drawing(s) will be provided by the 
Office upon request and payment of the necessary fee. 
Some of the features, advantages, and benefits of the 
present invention having been stated, others will become 
apparent as the description proceeds when taken in conjunc- 30 
tion with the accompanying drawings, presented for solely 
for exemplary purposes and not with intent to limit the inven-
tion thereto, and in which: 
FIG. 1, according to an embodiment of the present inven-
tion, is a TEM image of aminated (a) dextran and (b) silica 35 
coated iron oxide nanoparticles; the TEM images show that 
the dextran coated nanoparticles are rod shaped whereas the 
silica ones are spherical in nature (Bar=500 nm); 
FIG. 2 is a selected area electron diffraction (SAED) image 
of aminated (a) dextran and (b) silica coated iron oxide nano- 40 
particles (Bar=5 I/nm); the images show that the dextran 
coated particles are more crystalline than silica ones and 
consequently showing better magnetic relaxivity; 
FIG. 3 shows an XRD pattern of TO nanocrystals wherein 
the XRD shows that the peaks matches well with that of 45 
Fe30 4 as reported in literature; both dextran and silica coated 
particles show same XRD pattern; 
FIG. 4 provides an XPS spectruni of Fe30 4 nanocrystals 
where (a) shows the peaks due to Fe2p electrons and (b) 
shows that due to 01 s electron; both dextran and silica coated 50 
particles show same XPS pattern; thus, XPS confirms the 
formation of Fe3 0 4 nanocrystals in solution; 
FIG. S(a) shows a time dependent study, where after addi-
tion of 5 µg avidin in 0.5 µg IO-dextran biotin conjugate; the 
control contains 5 µg 0.1 M phosphate buffer, pH 7.4; S(b) 55 
shows a time dependent study after addition of 5 µg avidin in 
0.7 µg IO-silica biotin conjugate; the control contains 5 µg 0.1 
M phosphate buffer at pH 7.4; S(c) is a plot ofT2 (ms) vs. 
Time (min) after addition of 5 µg avidin in 0.5 µg ofboth silica 
and dextran coated biotinylated IO particles; S(d) depicts a 60 
dose dependent study where T2 was measured after 1 hr 
incubation of the 0.5 µg IO-dextran-biotinylated particles 
with avidin at different concentrations; detection limit of 
avidin=0.091 µg; S(e) shows a dose dependent study where 
T2 was measured after 1 hr incubation of the 0.5 µg IO-silica- 65 
biotinylated particles with avidin at different concentrations; 
detection limit of avidin=0.071 µg; 
FIG. 9(a) dynamic light scattering study ofDIONrods with 
ConA; (b) time dependent response in T2 ofDIONrods (200 
µ!, 0.002 mg Fe per ml) when treated with 10 µI ConA (1 mg 
in 1 ml PBS); (c) FTIR spectraoffreedextranandDIONrods. 
DETAILED DESCRIPTION OF THE PREFERRED 
EMBODIMENT 
The present invention will now be described more fully 
hereinafter with reference to the accompanying drawings, in 
which preferred embodiments of the invention are shown. 
Unless otherwise defined, all technical and scientific terms 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art to which this invention 
pertains. Although methods and materials similar or equiva-
lent to those described herein can be used in the practice or 
testing of the present invention, suitable methods and mate-
rials are described below. Any publications, patent applica-
tions, patents, or other references mentioned herein are incor-
porated by reference in their entirety. In case of conflict, the 
present specification, including any definitions, will control. 
In addition, the materials, methods and examples given are 
illustrative in nature only and not intended to be limiting. 
Accordingly, this invention may be embodied in many differ-
ent forms and should not be construed as limited to the illus-
trated embodiments set forth herein. Rather, these illustrated 
embodiments are provided so that this disclosure will be 
thorough and complete, and will fully convey the scope of the 
invention to those skilled in the art. Other features and advan-
tages of the invention will be apparent from the following 
detailed description, and from the claims. 
FIGS. 1, through 7(b) illustrate various aspects of the 
present invention. Herein, we disclose a simple water based 
technique forthe synthesis ofhigh quality Fe3 0 4 nanocrystals 
having high magnetic relaxivities. The method is based on the 
co-precipitation of ferric and ferrous chloride salts in an 
acidic environment, with the subsequent growth and mor-
phology of the iron oxide crystal being controlled by addition 
of a polymeric capping agent at a specific time. Two different 
kinds of capping agents ( dextran and silica) have been used in 
our experiments, showing that besides stabilization, the cap-
ping agents control the morphology and consequently mag-
netic property of the evolved particles. In our experiments, we 
found that rod-shaped particles of approximately 300 nm in 
length by about 100 nm in diameter with R2 relaxation of300 
mMs-1 were obtained when dextran was used as a capping 
agent. On the other hand, spherical nanoparticles of approxi-
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mately 150 run diameter with R2 relaxation of 150 mMs-1 
were obtained when a coating of aminated silica was used. 
6 
I. Synthetic Procedure 
The proper functionalization and bioconjugation of the 
nanoparticles with various targeting ligands resulted in robust 
nanosensors able to detect a molecular target by magnetic 
relaxation with high sensitivity. The high relaxivity of these 
particles allow us to do sensing experiments at a very low 
concentration of nanoparticles, with improved sensitivity and 
without precipitation of the particles because of their size. 
Furthermore, the fact that our facile synthetic method yields 10 
different sized particles depending on the polymer used is 
novel and can be used to generate multiple sizes and shapes of 
particles for further studies. 
Synthesis of Aminated Dextran Coated IO Nanoparticles 
A mixture ofiron salts containing 0.203 g FeC12 .4H20 and 
0.488 g FeCl3 .6H2 0 in HCl solution (88.7 12 N HCl in 2 ml 
water) was added to NH4 0H (830 µl in 15 ml N2 purged DI 
water) and stirred on a digital vortex mixer for 10 sec. Then, 
an aqueous solution of dextran (5 gin 10 ml water) was added 
to the mixture and stirred for 1 hr. Finally, the entire mixture 
was centrifuged for 30 minutes, to pellet large particles, and 
the supernatant was collected, filtered and washed several 
times with distilled water through an Amicon cell (Millipore 
ultrafiltration membrane YM-30 k). This process helps to get 
rid of the unbound dextran molecules. The dextran coated 
nanoparticle (3 mg, i.e. 3 ml 10 solution containing-I mg Fe 
per ml) was then crosslinked by treating with 200 pl epichlo-
rohydrin and 5 ml 0.5 M NaOH and the mixture was stirred 
In our first set of experiments, we optimized the synthetic 
protocol, including the order of addition (in situ vs. step- 15 
wise), and the time of addition of the dextran polymer. Our 
water-based synthetic protocol involves an acid-base reaction 
between an acidic solution ofiron salts and a basic solution of 
ammonium hydroxide. Upon mixing, the resulting solution 
becomes alkaline (pH=9.0), facilitating the formation of iron 20 
oxide nanocrystals. This initial formation of nanocrystals can 
occur either in the presence (in situ) or absence (step-wise) of 
dextran. 
vigorously at room temperature for 8 hrs. Afterwards, the 
particles were aminated by mixing 850 W, 30% ammonia and 
stirred overnight at RT to get aminated dextran coated 10 
particles. The free epichlorohydrin was removed by washing 
the solution repeatedly with distilled water using an Amicon 
cell. 
Synthesis of Aminated Silica Coated IO Nanoparticles: 
Since most synthetic procedures that afford stable and 
monodisperse nanoparticles use an in situ approach, we opted 
to try this approach first. In these experiments, a mixture of 
iron salts (FeCly6H2 0 and FeC12 .4H20) was dissolved in an 
aqueous solution of HCI. A dextran solution was prepared in 
aqueous anm10nia solution and placed on a digital vortex 
mixer. Finally the resulting iron salt solution was poured at 
one time into the ammonia solution of dextran under vigorous 
stirring. Following this protocol, we obtained poorly crystal-
line, spherical nanocrystals of20±5 run in diameter and poor 
R2 relaxivity 15 (<1 mMs-1). This poor relaxivity contrasts 
with the relaxivity obtained with other published in situ pro-
cedures where relaxivity values between 60-100 mMs-1 are 
obtained. 
Amixtureof0.203 gFeCl2 .4H20 and0.488 gFeCl3 .6H 0 
25 in HCl solution (88.7 µ112 N HCl in 2 ml water) was poU:ed 
into a solution of NH40H (830 µl in 15 ml N2 purged DI 
water) and stirred on a digital vortex mixer. After 10 sec of 
stirring 2680 µl tetraethylorthosilicate, 670 µl 3-(aminopro-
pyl)triethoxysilane and 6180 µl 3-(trihydroxysilyl)propylm-
30 ethylphosphonate were added to the iron oxide nanoparticle 
solution and stirred for 1 hr at 3000 rpm. Then, the solution 
w~s ce~t?fuged to remove large particles and washed finally 
with d1st1lled water through Ami con cell (Millipore ultrafil-
tration membrane YM-30 k). 
35 II. Advantages of the Present Method: 
1) Facile, cost effective, and green chemistry synthesis that 
does not require vigorous experimental conditions. 
2) Synthesis does not require the use of toxic reagents and 
therefore they are highly biocompatible. 
We then investigated if a step-wise approach might result in 
larger iron oxide nanocrystals and in improved R2 relaxivity. 
In this approach, a dextran solution was added at a particular 40 
time after initiating the nucleation of the iron oxide crystals. 
3) Good solubility and stability of resulting particles in 
~ater, p~osphate buffer saline and citrate buffer for a long 
time penod makes them suitable for biomedical applications. 
4) The resulting IO particles can be concentrated using 
ultrafiltration devices without inducing agglomeration of the 
45 nanoparticles. 
In initial optimization experiments, we measured T2 relaxiv-
ity (R2) and obtained TEM images of a series of dextran iron 
oxide nanoparticles prepared after adding dextran at different 
time~ (1, 10, 30 and 60 sec). Following this approach, we 
obtamed nanorods where their size, crystallinity and R2 
relaxivity improved with time of addition (Table 1 ). No sig-
nificant difference was observed between 30 and 60 seconds. 
Interestingly, the yield was reduced at 60 sec, based on mea-
surements of the concentration of iron in the solution which 
were performed as described. The most optimal pre~aration 
was obtained when dextran was added 30 seconds after initi-
ating the iron oxide nucleation, resulting in dextran iron oxide 
nanorods (DION rods) with an R2 of 300 mMs-1. 
TABLE 1 
Effect on T2 relaxivity compared to time of 
addition of dextran (8) to the reaction mixture. 
Time of addition ofDextran (8) 
Before adding ammonia 
1 sec 
10 sec 
30 sec 
60 sec 
<1 
50 
150 
300 
300 
5) The evolved particles are highly magnetic. Therefore 
they can be used at a very low concentration for biological 
applications. 
6) The aminated particles can be conjugated with proteins 
50 and other biomolecules for sensing application. 
7) Stable nanoparticles suspension of size range 100-500 
run (depending on experimental conditions) can be obtained. 
8) Using this protocol, we can obtain iron oxide crystals of 
defined size and shape by simply changing the polymer used 
55 as stabilizer/coating. For example, using dextran we favor 
formation of rods, while using silica we favor formation of 
spheres, under the same general experimental conditions. 
9) Other polymers can be used, potentially obtaining other 
shapes and sizes of nanoparticles. In particular, biodegrad-
60 able ~r bi~compatible polymers viz. polyvinyl alcohol, poly-
acryhc acid, among others can be used in the present method. 
65 
10) Resulting nanoparticles can be used for both in vitro 
and in vivo applications since synthetic procedure involves 
non-toxic materials. 
11) Both the silica coating and dextran coating nanopar-
ticles can achieve a strong water relaxation effect. Larger Rl 
and R2 are obtained. 
US 9,125,941 B2 
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12) Because of the larger R2 and Rl we can achieve a 
detectable MRI signal at low concentration of particles. 
III. Characterization 
A. Transmission Electron Microscopy (TEM) 
The results of examination of the evolved particles by TEM 
are shown in FIG. 1. Shown is the TEM image ofaminated (a) 
dextran and (b) silica coated iron oxide nanoparticles. The 
TEM images show that the dextran coated nanoparticles are 
rod shaped whereas the silica coated nanoparticles are 10 
approximately spherical in nature. (Bar=SOO nm). 
Sample 
10-dextran-
NH2 
10-silica-
NH2 
Size 
(nm) 
L-330 
B-100 
-150 
8 
TABLE2 
r1 r2 
(mM-1s') (ml vl - 1s-1) 
16.80 296 
12.43 145 
F. Additional Characterization Studies 
mmoles of arni-
no group per 
r2/rl gram of iron 
17.61 0.106 
11.66 0.152 
Subsequently, we studied the magnetic properties of the 
DIONrods. First, hysteresis loops, measured at three different 
temperatures (FIG. S(a)), demonstrated a coercivitiy of 
FIG. 2 depicts selected area electron diffraction (SAED) 
images of aminated (a) dextran and (b) silica coated iron 
oxide nanoparticles (Bar=S I/nm). The images show that the 
dextran coated particles are more crystalline than silica ones 
and consequently showing better magnetic relaxivity. 
B. X-Ray Diffraction Study (XRD) 
FIG. 3 shows the XRD pattern of IO nanocrystals. The 
XRD shows that the peaks match well with those ofFe3 0 4 , as 
reported in literature. Both dextran and silica coated particles 
show same XRD pattern. 
15 SOO±lO G at SK that disappeared at 100 Kand 200 K, which 
is typical of superparamagnetic behavior. Zero-field cooled 
(ZFC) and Field cooled (FC)--dc susceptibility studies (FIG. 
S(b)) show that the ZFC magnetic moment increased as the 
temperature increased, reaching a maximum at 28 K (the 
C. X-Ray Photoelectron Spectroscopy (XPS) 
20 blocking temperature, (TB) and then it decreased with further 
increase in temperature. In the FC process, above the block-
ing temperature (TB), the data followed the ZFC curve, but it 
deviated from ZFC curve below TB showing a slow increase 
in the moment with decreasing temperature. The maximum 
FIG. 4 provides an XPS spectrum of Fe30 4 nanocrystals 
where (a) shows the peaks due to Fe2p electrons and (b) 
shows that due to 01 s electron. Both dextran and silica coated 
particles show same XPS pattern. XPS confirms the forma-
tion ofFe30 4 nanocrystals in solution. 
25 found in the ZFC curve (at TB) is where a maximum number 
of particles exhibit superparamagnetic behavior. Below TB' 
the relaxation times of the particles are longer than the experi-
mental measurement time; hence the particles acquire a 
blocked state. In the ac susceptibility, both real and imaginary 
D. Quantification of Amines 
After amination of the resulting nanoparticles, it is impor-
tant to determine the amount of amine groups present per 
gram of iron oxide particles. The quantification of amine 
group on the surface ofIO particles is important, as they can 
30 components x'(T) and x"(T), at different frequencies ranging 
from 1 Hz to 1 kHz exhibited a frequency dependent maxi-
mum (FIG. S(c) and FIG. S(d)), which shifted to higher tem-
peratures with increasing frequency. This may be due to either 
spin glass or superparamagnetic behavior. To clearly distin-
35 guish between these two behaviors, the Mydosh parameter 
(<I>) was calculated from the real part of the ac susceptibility 
according to the equation: be used to conjugate to a series of targets according to the 
amount of amines. The amine groups present per gram of iron 
was determined through conjugation of the aminated par-
ticles with N-succinimidyl-3-(2-pyridyldithio )propionate 40 
(SPDP). Briefly, SOO µI aminated 10 (-1 mg Fe per ml) was 
mixed with 100 µI 0.1 M sodium phosphate buffer (pH 7.4) 
and 60 µI 7S mM SPDP in DMSO and kept for 2 hrs. The 
unbound nanoparticles and SPDP were removed by passing 
the solutions through a Sephadex PD-10 column. Afterwards, 45 
a portion of the IO-SPDP conjugate was treated with 7S µ120 
mM 1,4-dithio-DL-threitol (DTT) and stirred for 2 hrs. The 
reaction mixture was then passed through Microcon centrifu-
gal filter devices (YM 30) and absorbance of the filtrate was 
measured as previously described [Bioconjugate Chem. 50 
1999, 10 186]. 
NOTE: It has been observed that the aminated IO-silica 
and aminated dextran particles have about O.lS2 and 0.106 
mmoles of amines present per gram of iron respectively. The 
silica coated particles are more easily aminated as the syn- 55 
thesis involves coating materials containing aminating 
agents, such as 3-(aminopropyl)triethoxysilane (APTS). On 
the other hand, aminated dextran coated particles are synthe-
sized by first crosslinking the dextran coating and then ami-
nating the crosslinked nanoparticle with ammonia. The later 60 
procedure might introduce a limited number of amino groups 
to the nanoparticle, as opposed to the silica/ APTS protocol. 
We used the x'(l Hz) and x'(l kHz) data to calculate <I>, 
obtaining a value of0.072. Tm is the temperature correspond-
ing to the observed maximum in x'(l Hz) and llTm is the 
expected for superparamagnetic systems is -0.10, which fur-
ther corroborates that our DIONrods are superparamagnetic. 
The particle relaxation time follows the Arrhenius law, given 
by: 
(-!:.£) v = voexp ksT 
where llE/kB is the energy barrier and K is the experimental 
frequency. The data fitted well to a linear relation (inset of 
FIG. S(d)) yielding llE/kB-800±10K and T0 -2xl0-14 s, 
whereas 10-11 <T0<10-9 sis expected for superparamagnetic 
systems. The lower value ofT 0 is an indication ofinterparticle 
interactions present in the sample. Taken together, these 
results show that out DIONrods exhibit superparamagnetic 
behavior. 
E. Characteristic Properties of Aminated Dextran and 
Silica Coated Iron Oxide Nanoparticles 
The characteristics of the aminated dextran and silica 
coated iron oxide particles are shown in Table 2, below. 
Regarding FIG. 8, panel (a) shows hysteresis loops 
65 obtained at temperatures SK, lOOK and 200K, panel (b) 
depicts zero field cooled and field cooled magnetic suscepti-
bilities in an external magnetic field H=200 G, panel (c) 
US 9,125,941 B2 
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shows real and ( d) imaginary components of ac susceptibility 
at different frequencies. The inset of FIG. S(d) shows the 
Arrhenius plot obtained from the imaginary component of 
susceptibility measurements. 
Furthermore, we performed experiments to assess the qual-
ity and stability of our nanorods. First, the presence of dextran 
10 
have more amine groups on their surface. Therefore, they are 
more biotinylated and can conjugate with avidin to a greater 
extent. 
on nanorod surfaces was confirmed by performing clustering 
experiments with Concanavalin-A (ConA). Specifically, the 
presence of dextran on nanoparticles can be identified via 
ConA-induced nanoparticle clustering, due to the strong 10 
affinity and multivalency of ConA towards carbohydrates, 
such as dextran. DLS experiments (FIG. 9(a)) show a time-
dependent increase in particle size distribution upon ConA 
administration, due to formation ofnanoparticle assemblies. 15 
Most importantly, a fast and reproducible change in T2 relax-
ation time was observed (FIG. 9(b)), not only indicating the 
association of dextran with the nanoparticle, but indicating 
the feasibility of our DIONrods as magnetic relaxation sen-
FIG. S(d) presents a dose dependent study where T2 was 
measured after 1 hr incubation of the 0.5 µg IO-dextran-
biotinylated particles with avidin at different concentrations. 
The detection limit of avidin=0.091 µg. 
FIG. S(e) shows another dose dependent study where T2 
was measured after 1 hr incubation of the 0.5 µg IO-silica-
biotinylated particles with avidin at different concentrations. 
Detection limit of avidin=0.071 µg. NOTE: Here also, the 
silica coated biotinylated 10 particles show better sensitivity 
with respect to dextran coated ones for avidin and can detect 
the presence of avidin to a lower concentration. 
B. Conjugation of Protein G withAminated Nanoparticles 
To conjugate IO nanoparticles with protein G at first the 
particles are to be dissolved in DMSO to conjugate with 
disuccinimidyl suberate (DSS). The DMSO suspensionofthe 
sors. 
With reference to FIG. 9(a), shown is a dynamic light 
scattering study ofDIONrods with ConA; FIG. 9(b) shows 
the time dependent response in T2 of DIONrods (200 µl, 
0.002 mg Fe per ml) when treated with 10 µl ConA (1 mg in 
1 ml PBS); FIG. 9(c) shows FTIR spectra of free dextran and 
DIONrods. The FT-IR experiments further confirmed the 
presence of characteristic dextran peaks on the DIONrods 
preparations. Most importantly, the prepared DIONrods can 
be concentrated in PBS by ultrafiltration, obtaining highly 
concentrated preparations without nanoparticle precipitation 
even upon storage at 4° C. for over twelve months. Taken 
together, these results demonstrate the robustness of the dex-
tran coating on the nanorods, making them suitable for bio-
medical applications. 
IV. Applications 
A. Conjugation with Biotin: 
To conjugate biotin onto the aminated IO nanoparticles, the 
nanoparticle solution (1 ml) was incubated with Sulfo-N-
hydroxysuccinimide-LC-Biotin (Pierce, 1 mg) for 2 hrs. The 
solution was then centrifuged at 13 .2 k rpm for 30 min and the 
supernatant was discarded. The pellet was then redispersed in 
phosphate buffer (pH 7.4) to obtain biotinylated nanopar-
ticles. The centrifugation and redispersion were repeated 
three times to get rid of unbound biotin molecules. The pres-
ence of biotin on the surface of nanoparticles was assessed via 
biotin-avidin interaction through magnetic relaxation. The 
biotin-avidin interaction is used as a model system to prove 
the utility of our nanoparticles as magnetic relaxation 
switches. The binding of avidin to the biotin of the nanopar-
ticles causes clustering of the nanoparticles with a concomi-
tant decrease in T2 relaxation time. The biotinylated particles 
were targeted with avidin and the changes in T2 was mea-
sured in a relaxometer at 0 .4 7 T. It has been observed that even 
a very low concentration of the biotinylated particles can 
sense avidin through magnetic relaxometer. 
In that regard, FIG. S(a) shows a time dependent study. 
After addition of 5 µg avidin in 0.5 µg IO-dextran biotin 
conjugate. The control contains 5 µl 0.1 M phosphate buffer at 
pH 7.4. FIG. S(b) shows another time dependent study, this 
after addition of 5 µg avidin in 0.7 µg IO-silica-biotin conju-
gate. The control contains 5 µl 0.1 M phosphate buffer, pH 
7.4. FIG. S(c) shows a plot ofT2 (ms) vs. Time (min) after 
addition of 5 µg avidin in 0.5 µg of both silica and dextran 
coated biotinylated IO particles. NOTE: At this concentration 
of iron, aminated silica coated particles show greater sensi-
tivity than the dextran coated ones, as silica coated particles 
20 IO nanoparticles was obtained by combining 1 ml of ami-
nated nanoparticles with 1 ml isopropanol, mixing well and 
spinning down at 13 .2 k rpm for 1 hr. The supernatant was 
decanted and the pellet was dissolved completely in 500 µl 
DMSO. The suspension was again treated with isopropanol 
25 and spinned down. The centrifugation and redispersion were 
repeated three times to get rid of trace amounts of water. 
Afterwards the nanoparticle pellets were again redispersed in 
500 µl DMSO and to that suspension 5 µl of disuccinimidyl 
suberate (DSS, 5.88 mg in 128 µl DMSO) was added. The 
30 mixture was stirred well and allowed to react for 30 mins to 
link DSS on the surface of the particles. Then the DSS linked 
particles were treated with 1.5 ml isopropanol and mixed 
properly. The reaction mixture was centrifuged and pellets 
were again dispersed in DMSO. The centrifugation andredis-
35 persion was repeated for 3 times to eliminate excess DSS. 
Finally, the pellets were redispersed in protein G (Sigma) 
solution (1 mg protein G in 1 ml, 200 mM phosphate buffer, 
pH 8.0). The mixture was kept for 1 hr at room temperature 
and then overnight at 4° C. to obtain the protein G function-
40 alized particles. 
The synthesized protein G functionalized nanoparticles 
were targeted with an antibody against protein G and the 
changes in T2 were measured (FIGS. 6a and 6b). FIG. 6(a) 
shows a time dependent study: after addition of 1 µl of anti-
45 body against protein Gin 0.42 ug IO-dextran-protein G par-
ticles. FIG. 6(b) is a time dependent study, where after addi-
tion of 1 µl of antibody against protein Gin 0.66 µg IO-silica-
protein G particles. NOTE: When an antibody specific to 
protein G was added to protein G functionalized nanopar-
50 ti cl es, a concomitant decrease was observed due to clustering 
of the particles. The antibody binds to the proteins and causes 
clustering with other antibody conjugated particles. Conse-
quently an instantaneous decrease in T2 was observed. The 
silica coated protein G functionalized particles show a greater 
55 decrease as compared to dextran coated ones. The presence of 
more amines on their surface of silica coated particles made 
them more easily bounded to protein G and causes a greater 
change in T2 relaxation time when treated with antibody. 
C. Detection of Mycobacterium avium Paratuberculosis 
60 (MAP) 
To test the capability of our particles in sensing a "real" 
target we plarmed to use the newly synthesized protein G 
conjugated particles to sense the presence of bacteria in fluid 
media. As a model system, we used Mycobacterium avium 
65 paratuberculosis (MAP). A MAP specific magnetic nanosen-
sor was prepared by conjugating an anti-MAP antibody to 
protein G-IO nanoparticles. 
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Up~n addi~ion of the bacteria to a solution containing the 
bactena-spec1fic nanosensors, a rapid and sensitive detection 
of the bacterial target was achieved via changes in T2. This 
observation proves that our relatively large iron oxide nano-
P.art.icles can be used to detect a molecular target in solution, 
s1m1lar to previously reported studies that use smaller nano-
particles in the range of30-50 nm [Perez, J.M., Nat Biotech-
nol. 2002, 20(8): p. 816-20]. 
FIG. 7 (a) presents the results of yet another time dependent 
study, after addition of 51.25 CFU MAP in 0.54 µg IO- 10 
dextran-protein G particles. The control=! p.1 phosphate 
buffer, pH 7.4. IO-dextran-Protein G was conjugated with an 
antibody specific to MAP and then MAP was added. FIG. 
7(b) is a time dependent study, showing after addition of 
51.25 CFUMAP in0.82 µgIO-silica-proteinGparticles. The 15 
control=! µl phosphate buffer, pH 7.4. IO-silica-protein G 
was conjugated with antibody specific to MAP and then MAP 
was added. 
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4. The method of claim 1, wherein the biocompatible poly-
mer comprises silicon. 
5. The method of claim 1, wherein the biocompatible poly-
mer is selected from dextran, polyvinyl alcohol, polyacrylic 
acid, a silicon-based polymer and combinations thereof. 
6. The method of claim 1, wherein the biocompatible poly-
m_er is sel~cted from tetraethylorthosilicate, 3-(aminopropyl) 
tnethoxys1lane, 3-( trihydroxysy lily l)propy lmethy lphospho-
nate and combinations thereof. 
. 7. A.suspension of rod-shaped nanoparticles comprising 
iron oxide coated with a crosslinked aminated biocompatible 
polymer, said nanoparticles having a major dimension and a 
minor dimension, and having a relatively high magnetic R2 
relaxation. 
8. The suspension of claim 7, wherein said iron oxide forms 
a superparamagnetic core of the rod-shaped nanoparticles. 
9. The suspension of claim 7, wherein said biocompatible 
polymer is dextran. 
10. The suspension of claim 7, wherein said biocompatible 
polymer is selected from dextran, polyvinyl alcohol poly-
acrylic acid, and combinations thereof. ' 
Accordingly, in the drawings and specification there have 
been disclosed typical preferred embodiments of the inven- 20 
ti on and although specific terms may have been employed, the 
terms are used in a descriptive sense only and not for purposes 
of limitation. The invention has been described in consider-
able detail with specific reference to these illustrated embodi-
ments. It will be apparent, however, that various modifica-
tions and changes can be made within the spirit and scope of 
the invention as described in the foregoing specification and 
11. The suspension of claim 7, wherein the minor dimen-
sion of the rod-shaped nanoparticles is approximately 113 of 
25 the major dimension. 
. 12. The suspension of claim 7, wherein the major dimen-
s10n of the rod-shaped nanoparticles is approximately in the 
range of 100-500 nm. as defined in the appended claims. 
The invention claimed is: 
1. An aqueous method of making polymer coated super-
paramagnetic nanoparticles, the method comprising: 
providing a mixture of iron salts in aqueous hydrochloric 
acid; 
13. T.he suspension of claim 7, wherein the relatively high 
30 magnetic R2 relaxation is in the approximate range of 300-400 mMs-1. 
combining a solution of ammonium hydroxide with the 
mixture and stirring for a time sufficient for formation of 35 
a suspension of iron oxide nanoparticles; 
14. The suspension of claim 7, wherein the rod-shaped 
nanoparticles further comprise a ligand conjugated to the 
crosslinked aminated dextran. 
15. T~e suspension of claim 7, wherein the rod-shaped 
nanopart1cles further comprise a protein G ligand conjugated 
to the crosslinked aminated dextran. ad~ing to the suspension one or more aqueous biocompat-
1ble polymers thereby coating the nanoparticles with 
~olyn_ier, wherein optionally at least one of the polymers 
1s ammated; 
centrifuging the suspension, rendering a supernatant with-
out large particles; 
filtering the supernatant through an ultrafiltration mem-
brane and collecting the filtrate containing the polymer 
coated nanoparticles; 
crosslinking the polymer coating by treating the nanopar-
ticles with epichlorohydrin and sodium hydroxide while 
mixing for up to about eight hours; 
aminating any un-aminated crosslinked polymer remain-
ing by treating with ammonia; and 
removing free epichlorohydrin from the suspension. 
2. The method of claim 1, wherein the iron salts are 
selected from FeC12 , FeCl3 , and combinations thereof. 
3. The method of claim 1, wherein the biocompatible poly-
mer comprises dextran. 
16. A suspension of superparamagnetic nanoparticles 
wherein said nanoparticles comprise a core of iron oxide 
40 coated :-"ith a crosslinked aminated silicon-containing poly-
mer, said nanoparticles having a size of approximately from 
100 nm to 500 nm. 
17. The suspension of superparamagnetic nanoparticles of 
claim. 16, wherein the nanoparticles are approximately 
45 sphencal and the size is a diameter. 
18. The suspension of superparamagnetic nanoparticles of 
claim 16, wherein said nanoparticles have an R2 relaxation of 
approximately 150 mMs-1. 
~9. The suspension of superparamagnetic nanoparticles of 
50 claim 16, further comprising a ligand conjugated to the 
crosslinked aminated silicon-containing polymer. 
20. The suspension of superparamagnetic nanoparticles of 
claim 16, further comprising a protein G ligand conjugated to 
the aminated silicon-containing polymer. 
* * * * * 
